Trial Profile
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms VELVET
- Sponsors Roche
- 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.
- 01 Oct 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.